Impact of the Endocannabinoid System on Bone Formation and Remodeling in p62 KO Mice.
CB2
JWH133 (PubChem CID: 6918505)
Paget’s disease of bone (PDB)
bone
cannabinoid receptor
osteoblast (OB)
osteoclast (OC)
p62 (sequestosome 1(SQSTM1)
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2022
2022
Historique:
received:
19
01
2022
accepted:
28
02
2022
entrez:
8
4
2022
pubmed:
9
4
2022
medline:
9
4
2022
Statut:
epublish
Résumé
Several studies have shown that the G-protein coupled cannabinoid receptor CB2 and its interaction partner p62 are molecularly involved in bone remodeling processes. Pharmacological activation of the CB2 receptor enhanced bone volume in postmenopausal osteoporosis and arthritis models in rodents, whereas knockout or mutation of the p62 protein in aged mice led to Paget's disease of bone-like conditions. Studies of pharmacological CB2 agonist effects on bone metabolism in p62 KO mice have not been performed to date. Here, we assessed the effect of the CB2-specific agonist JWH133 after a short-term (5 days in 3-month-old mice) or long-term (4 weeks in 6-month-old mice) treatment on structural, dynamic, and cellular bone morphometry obtained by μCT of the femur and histomorphometry of the vertebral bodies in p62 KO mice and their WT littermates
Identifiants
pubmed: 35392569
doi: 10.3389/fphar.2022.858215
pii: 858215
pmc: PMC8980328
doi:
Types de publication
Journal Article
Langues
eng
Pagination
858215Informations de copyright
Copyright © 2022 Keller, Yorgan, Rading, Schinke and Karsak.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Endocrinology. 2008 Nov;149(11):5619-26
pubmed: 18635663
J Biol Chem. 2018 Jun 15;293(24):9530-9541
pubmed: 29555685
Hum Mol Genet. 2008 Dec 1;17(23):3708-19
pubmed: 18765443
J Biol Chem. 2003 Sep 5;278(36):34568-81
pubmed: 12813044
Calcif Tissue Int. 2010 Jun;86(6):470-83
pubmed: 20405109
Int J Mol Sci. 2021 Sep 21;22(18):
pubmed: 34576321
J Biol Chem. 2007 Aug 17;282(33):24131-45
pubmed: 17580304
Front Physiol. 2021 Aug 27;12:696852
pubmed: 34512376
J Cell Physiol. 2020 Oct;235(10):7516-7529
pubmed: 32100883
Cell Metab. 2011 Jan 5;13(1):23-34
pubmed: 21195346
Nat Med. 2005 Jul;11(7):774-9
pubmed: 15908955
Cell Commun Signal. 2020 Jan 15;18(1):9
pubmed: 31941496
Pharmacol Res. 2012 Dec;66(6):457-62
pubmed: 22841931
PLoS One. 2016 Sep 09;11(9):e0155076
pubmed: 27611972
Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):696-701
pubmed: 16407142
FEBS J. 2021 Dec;288(24):6927-6941
pubmed: 33332721
Mol Endocrinol. 2009 Oct;23(10):1668-80
pubmed: 19589897
Trends Biochem Sci. 2007 Feb;32(2):95-100
pubmed: 17174552
J Biol Chem. 2015 Sep 4;290(36):22049-60
pubmed: 26195631
Mamm Genome. 2017 Dec;28(11-12):476-486
pubmed: 28913652
Curr Mol Pharmacol. 2014;7(1):67-80
pubmed: 25023974
J Clin Invest. 2005 Feb;115(2):200-8
pubmed: 15690073
Genome Biol. 2013 Jul 31;14(7):R82
pubmed: 23902802
Birth Defects Res B Dev Reprod Toxicol. 2007 Dec;80(6):425-50
pubmed: 18157899
Dev Cell. 2004 Feb;6(2):303-9
pubmed: 14960283
J Bone Miner Res. 2013 Jan;28(1):92-107
pubmed: 22903605
Br J Pharmacol. 2019 Dec;176(23):4537-4547
pubmed: 31368508
EMBO J. 2000 Apr 3;19(7):1576-86
pubmed: 10747026
Handb Exp Pharmacol. 2015;231:1-37
pubmed: 26408156
Calcif Tissue Int. 2014 Mar;94(3):259-68
pubmed: 24036631
Sci Rep. 2021 Sep 15;11(1):18349
pubmed: 34526596
Dis Model Mech. 2018 Aug 23;11(9):
pubmed: 30154079
Aging Cell. 2017 Oct;16(5):1051-1061
pubmed: 28752643
Endocrinology. 2011 Jun;152(6):2141-9
pubmed: 21447627
Bone. 2015 Nov;80:14-18
pubmed: 26453494
Calcif Tissue Int. 2014 Apr;94(4):423-32
pubmed: 24370613
Front Pharmacol. 2018 Nov 06;9:1292
pubmed: 30459625
J Cell Sci. 2018 Nov 5;131(21):
pubmed: 30397181
Calcif Tissue Int. 2019 May;104(5):483-500
pubmed: 30671590
Nat Commun. 2017 Jul 24;8(1):102
pubmed: 28740232
Cell Metab. 2006 Mar;3(3):211-22
pubmed: 16517408
Endocr Rev. 2013 Aug;34(4):501-24
pubmed: 23612225
Br J Pharmacol. 2008 Jan;153(2):182-8
pubmed: 18071301
Pharmacol Res. 2022 Jan;175:105928
pubmed: 34800625
Pharmacol Res. 2015 Sep;99:194-201
pubmed: 26117426
Calcif Tissue Int. 2020 Apr;106(4):431-443
pubmed: 31901965
J Bone Miner Res. 2019 Apr;34(4):739-751
pubmed: 30508319
Br J Pharmacol. 2022 May;179(10):2223-2239
pubmed: 34811740
J Mol Signal. 2012 Jan 04;7:1
pubmed: 22216904
Nat Rev Rheumatol. 2010 Jan;6(1):50-9
pubmed: 20046206
Calcif Tissue Int. 2009 Jan;84(1):20-37
pubmed: 19067022
Proc Natl Acad Sci U S A. 2020 Mar 3;117(9):5006-5015
pubmed: 32071246
Nat Commun. 2017 Jan 03;8:13958
pubmed: 28045021
Front Mol Neurosci. 2019 Sep 20;12:224
pubmed: 31616248
J Bone Miner Res. 2006 Dec;21 Suppl 2:P38-44
pubmed: 17229007
Biomed Pharmacother. 2021 Apr;136:111283
pubmed: 33482616